{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:15:29Z","timestamp":1781374529521,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s10147-009-0884-5","type":"journal-article","created":{"date-parts":[[2009,12,4]],"date-time":"2009-12-04T06:41:47Z","timestamp":1259908907000},"page":"545-550","source":"Crossref","is-referenced-by-count":3,"title":["Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era"],"prefix":"10.1007","volume":"14","author":[{"given":"Ridvan","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahir","family":"Ozkalemkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"Ozkocaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahsin","family":"Yakut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulya Ozturk","family":"Nazlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferah","family":"Budak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Pekgoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhat","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Karkucak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulay","family":"Ozcelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Tunali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,5]]},"reference":[{"key":"884_CR1","first-page":"1248","volume":"9","author":"G. Marcucci","year":"2003","unstructured":"Marcucci G, Perrotti D, Caligiuri MA (2003) Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary. Clin Cancer Res 9:1248\u20131252","journal-title":"Clin Cancer Res"},{"key":"884_CR2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"B.J. Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al. (2006) Five-year follow up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"884_CR3","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","volume":"110","author":"J.M. Goldman","year":"2007","unstructured":"Goldman JM (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110:2828\u20132837","journal-title":"Blood"},{"key":"884_CR4","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cncr.22569","volume":"109","author":"H. Kantarjian","year":"2007","unstructured":"Kantarjian H, O\u2019Brien S, Talpaz M, et al. (2007) Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 109: 1556\u20131560","journal-title":"Cancer"},{"key":"884_CR5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cancergencyto.2004.06.011","volume":"157","author":"U. Bacher","year":"2005","unstructured":"Bacher U, Haferlach T, Hiddemann W, et al. (2005) Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet 157: 53\u201361","journal-title":"Cancer Genet Cytogenet"},{"key":"884_CR6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0165-4608(03)00198-5","volume":"147","author":"C. Herens","year":"2003","unstructured":"Herens C, Baron F, Croisiau C, et al. (2003) Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. Cancer Genet Cytogenet 147:78\u201380","journal-title":"Cancer Genet Cytogenet"},{"key":"884_CR7","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","volume":"110","author":"E. Jabbour","year":"2007","unstructured":"Jabbour E, Kantarjian HM, Abruzzo LV, et al. (2007) Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110:2991\u20132995","journal-title":"Blood"},{"key":"884_CR8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","volume":"107","author":"E. Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S, et al. (2006) Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107:480\u2013482","journal-title":"Blood"},{"key":"884_CR9","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.22661","volume":"109","author":"E. Jabbour","year":"2007","unstructured":"Jabbour E, Cortes JE, Giles FJ, et al. (2007) Current and emerging treatment options in chronic myeloid leukemia. Cancer 109: 2171\u20132181","journal-title":"Cancer"},{"key":"884_CR10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cncr.22046","volume":"107","author":"G. Alimena","year":"2006","unstructured":"Alimena G, Breccia M, Latagliata R, et al. (2006) Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer 107:1008\u20131013","journal-title":"Cancer"},{"key":"884_CR11","doi-asserted-by":"crossref","unstructured":"Ilaria RL Jr (2005) Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematology Am Soc Hematol Educ Program 188\u2013194","DOI":"10.1182\/asheducation-2005.1.188"},{"key":"884_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cncr.11477","volume":"98","author":"H. Kantarjian","year":"2003","unstructured":"Kantarjian H, O\u2019Brien S, Cortes J, et al. (2003) Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer 98:81\u201385","journal-title":"Cancer"},{"key":"884_CR13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20096","volume":"76","author":"T. Higashi","year":"2004","unstructured":"Higashi T, Tsukada J, Kato C, et al. (2004) Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 76:275\u2013278","journal-title":"Am J Hematol"},{"key":"884_CR14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.5858\/2004-128-980-POCMLT","volume":"128","author":"Y. Xu","year":"2004","unstructured":"Xu Y, Wahner AE, Nguyen PL (2004) Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate. Arch Pathol Lab Med 128:980\u2013985","journal-title":"Arch Pathol Lab Med"},{"key":"884_CR15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ajh.20777","volume":"82","author":"B.J. Bryant","year":"2007","unstructured":"Bryant BJ, Alperin JB, Elghetany MT (2007) Paraplegia as the presenting manifestation of extramedullary megakaryoblastic transformation of previously undiagnosed chronic myelogenous leukemia. Am J Hematol 82:150\u2013154","journal-title":"Am J Hematol"},{"key":"884_CR16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2169\/internalmedicine.42.740","volume":"42","author":"K. Naito","year":"2003","unstructured":"Naito K, Mori T, Miyazaki K, et al. (2003) Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571). Intern Med 42:740\u2013742","journal-title":"Intern Med"},{"key":"884_CR17","first-page":"146","volume":"75","author":"D. Inverardi","year":"1990","unstructured":"Inverardi D, Lazzarino M, Morra E, et al. (1990) Extramedullary disease in Ph\u2019-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance. Haematologica 75: 146\u2013148","journal-title":"Haematologica"},{"key":"884_CR18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.leukres.2007.01.022","volume":"31","author":"A. Pawarode","year":"2007","unstructured":"Pawarode A, Sait SN, Nganga A, et al. (2007) Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. Leuk Res 31:1589\u20131592","journal-title":"Leuk Res"},{"key":"884_CR19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0165-4608(03)00214-0","volume":"148","author":"R.V. Iyer","year":"2004","unstructured":"Iyer RV, Sait SN, Matsui S, et al. (2004) Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet 148:29\u201334","journal-title":"Cancer Genet Cytogenet"},{"key":"884_CR20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ajh.10227","volume":"71","author":"B.S. Ko","year":"2002","unstructured":"Ko BS, Tang JL, Lee FY, et al. (2002) Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome\/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan. Am J Hematol 71:291\u2013299","journal-title":"Am J Hematol"},{"key":"884_CR21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/TCRM.S1527","volume":"4","author":"M. Henkes","year":"2008","unstructured":"Henkes M, van der Kuip H, Aulitzky WE (2008) Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag 4:163\u2013187","journal-title":"Ther Clin Risk Manag"},{"key":"884_CR22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"H.M. Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, Giles F, et al. (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145:913\u2013923","journal-title":"Ann Intern Med"},{"key":"884_CR23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10147-007-0699-1","volume":"12","author":"T. Maekawa","year":"2007","unstructured":"Maekawa T, Ashihara E, Kimura S (2007) The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 12: 327\u2013340","journal-title":"Int J Clin Oncol"},{"key":"884_CR24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2007-0170","volume":"13","author":"P. Ramirez","year":"2008","unstructured":"Ramirez P, DiPersio JF (2008) Therapy options in imatinib failures. Oncologist 13:424\u2013434","journal-title":"Oncologist"},{"key":"884_CR25","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000140633","volume":"119","author":"J.M. Goldman","year":"2008","unstructured":"Goldman JM, Melo JV (2008) BCR-ABL in chronic myelogenous leukemia-how does it work? Acta Haematol 119:212\u2013217","journal-title":"Acta Haematol"},{"key":"884_CR26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/cncr.21235","volume":"104","author":"H.M. Kantarjian","year":"2005","unstructured":"Kantarjian HM, Bueso-Ramos CE, Talpaz M, et al. (2005) Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 104:777\u2013780","journal-title":"Cancer"},{"key":"884_CR27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/10428190500097581","volume":"46","author":"H.M. Kantarjian","year":"2005","unstructured":"Kantarjian HM, Bueso-Ramos CE, Talpaz M, et al. (2005) The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 46:993\u2013997","journal-title":"Leuk Lymphoma"},{"key":"884_CR28","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.20380","volume":"101","author":"C.E. Bueso-Ramos","year":"2004","unstructured":"Bueso-Ramos CE, Cortes J, Talpaz M, et al. (2004) Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 101:332\u2013336","journal-title":"Cancer"},{"key":"884_CR29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2559.2005.02119.x","volume":"46","author":"J. Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. (2005) Bone marrow changes in chronic myelogenous leukaemia after longterm treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 46:540\u2013550","journal-title":"Histopathology"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-009-0884-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-009-0884-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-009-0884-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T10:54:24Z","timestamp":1634295264000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-009-0884-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["884"],"URL":"https:\/\/doi.org\/10.1007\/s10147-009-0884-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}